ATE439863T1 - Ophthalmische zusammensetzungen von parasympathischen stimulantia und entzündungshemmer zur verwendung bei der behandlung von presbyopie - Google Patents
Ophthalmische zusammensetzungen von parasympathischen stimulantia und entzündungshemmer zur verwendung bei der behandlung von presbyopieInfo
- Publication number
- ATE439863T1 ATE439863T1 AT06026169T AT06026169T ATE439863T1 AT E439863 T1 ATE439863 T1 AT E439863T1 AT 06026169 T AT06026169 T AT 06026169T AT 06026169 T AT06026169 T AT 06026169T AT E439863 T1 ATE439863 T1 AT E439863T1
- Authority
- AT
- Austria
- Prior art keywords
- presbyopia
- treatment
- ophthalmic
- parasympathic
- stimulant
- Prior art date
Links
- 230000003110 anti-inflammatory effect Effects 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 201000010041 presbyopia Diseases 0.000 title abstract 2
- 230000001734 parasympathetic effect Effects 0.000 title 1
- 229940121363 anti-inflammatory agent Drugs 0.000 abstract 1
- 239000002260 anti-inflammatory agent Substances 0.000 abstract 1
- 239000000734 parasympathomimetic agent Substances 0.000 abstract 1
- 230000001499 parasympathomimetic effect Effects 0.000 abstract 1
- 229940005542 parasympathomimetics Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/08—Oxides; Hydroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/38—Silver; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06026169A EP1938839B1 (de) | 2006-12-18 | 2006-12-18 | Ophthalmische Zusammensetzungen von parasympathischen Stimulantia und Entzündungshemmer zur Verwendung bei der Behandlung von Presbyopie |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE439863T1 true ATE439863T1 (de) | 2009-09-15 |
Family
ID=37969963
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06026169T ATE439863T1 (de) | 2006-12-18 | 2006-12-18 | Ophthalmische zusammensetzungen von parasympathischen stimulantia und entzündungshemmer zur verwendung bei der behandlung von presbyopie |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US8524758B2 (de) |
| EP (1) | EP1938839B1 (de) |
| JP (1) | JP5769375B2 (de) |
| AT (1) | ATE439863T1 (de) |
| AU (1) | AU2007335919B2 (de) |
| BR (1) | BRPI0720355B8 (de) |
| CA (1) | CA2672985C (de) |
| DE (1) | DE602006008643D1 (de) |
| DK (1) | DK1938839T3 (de) |
| ES (1) | ES2329161T3 (de) |
| MX (1) | MX2009006505A (de) |
| PT (1) | PT1938839E (de) |
| WO (1) | WO2008075149A2 (de) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0724558D0 (en) | 2007-12-15 | 2008-01-30 | Sharma Anant | Optical correction |
| US20100298335A1 (en) * | 2009-05-22 | 2010-11-25 | Kaufman Herbert E | Preparations and Methods for Ameliorating or Reducing Presbyopia |
| IN2014CN02961A (de) * | 2011-09-20 | 2015-07-03 | Altavista Inst De Invest Medica S A S | |
| EP2816965B1 (de) * | 2012-02-25 | 2020-08-26 | Thrufocus Optics, Inc. | Vorrichtungen zur verbesserung der sehstärke mittels laser-photomiosis |
| US10744034B2 (en) * | 2012-04-25 | 2020-08-18 | Gregg S. Homer | Method for laser treatment for glaucoma |
| US10507245B2 (en) * | 2012-07-19 | 2019-12-17 | Luis Felipe Vejarano Restrepo | Ophthalmic formulation and method for ameliorating presbyopia |
| US10307408B2 (en) | 2013-08-28 | 2019-06-04 | Presbyopia Therapies, LLC | Contact lens compositions and methods for the treatment of presbyopia |
| US9089562B2 (en) | 2013-08-28 | 2015-07-28 | Presbyopia Therapies Llc | Compositions and methods for the treatment of presbyopia |
| US9314427B2 (en) | 2013-08-28 | 2016-04-19 | Presbyopia Therapies Llc | Compositions and methods for the improvement of distance vision and the treatment of refractive errors of the eye |
| US10617763B2 (en) | 2013-08-28 | 2020-04-14 | Presbyopia Therapies, LLC | Compositions and methods for the treatment of presbyopia |
| US9833441B2 (en) | 2013-08-28 | 2017-12-05 | Presbyopia Therapies Llc | Compositions and methods for the treatment of presbyopia |
| US10064818B2 (en) | 2013-08-28 | 2018-09-04 | Presbyopia Therapies, LLC | Compositions and methods for the treatment of presbyopia |
| US9844537B2 (en) | 2013-08-28 | 2017-12-19 | Presbyopia Therapies Llc | Compositions and methods for the treatment of presbyopia |
| US9968594B2 (en) | 2013-08-28 | 2018-05-15 | Presbyopia Therapies Llc | Compositions and methods for the treatment of presbyopia |
| US9320709B2 (en) | 2013-08-28 | 2016-04-26 | Presbyopia Therapies Llc | Storage stable compositions and methods for the treatment of refractive errors of the eye |
| US11179327B2 (en) | 2013-08-28 | 2021-11-23 | Lenz Therapeutics, Inc. | Compositions and methods for the treatment of presbyopia |
| AU2014332488B2 (en) | 2013-10-09 | 2017-03-09 | Johnson Living Trust Dated October 26, 2001, Leonidas A. Johnson, Trustee | Methods and compositions for treating and preventing signs or symptoms of eye disease |
| ES2538551B1 (es) * | 2013-12-20 | 2016-01-13 | Eurocanarias Oftalmológica, Sl | Composición Oftálmica para la corrección de la presbicia |
| EP3104851A1 (de) * | 2014-02-11 | 2016-12-21 | Orasis Pharmaceuticals Ltd. | Ophthalmische pharmakologische zusammensetzung zur verwendung bei der korrektur von altersweitsichtigkeit und dessen verabreichung |
| US12653779B2 (en) | 2015-06-18 | 2026-06-16 | Lenz Therapeutics Operations, Inc. | Compositions and methods for the treatment of presbyopia |
| CA2987787C (en) | 2015-06-18 | 2023-06-27 | Presbyopia Therapies, LLC | Compositions for the improvement of distance vision and the treatment of refractive errors of the eye |
| US20190000808A1 (en) * | 2015-07-13 | 2019-01-03 | Allergan, Inc. | Composition and methods for the treatment of blephopharoptosis |
| KR102472774B1 (ko) | 2016-08-19 | 2022-11-30 | 오라시스 파마슈티칼스 엘티디. | 안과용 약학 조성물 및 이와 관련된 용도 |
| US20180104098A1 (en) * | 2016-10-13 | 2018-04-19 | Ronald Michael Kurtz | System for nonpharmacologic long-term constriction of a pupil |
| US10406380B2 (en) * | 2016-10-13 | 2019-09-10 | Ronald Michael Kurtz | Method for nonpharmacologic temporary constriction of a pupil |
| US20180104508A1 (en) * | 2016-10-13 | 2018-04-19 | Ronald Michael Kurtz | Optical system for nonpharmacologic constriction of a pupil |
| US10925479B2 (en) | 2016-10-13 | 2021-02-23 | Ronald Michael Kurtz | Networked system of mobile communication platforms for nonpharmacologic constriction of a pupil |
| US10406352B2 (en) * | 2016-10-13 | 2019-09-10 | Ronald Michael Kurtz | System for temporary nonpharmacologic constriction of the pupil |
| US20180104099A1 (en) * | 2016-10-13 | 2018-04-19 | Ronald Michael Kurtz | Digitally controlled optical system for nonpharmacologic constriction of a pupil |
| JP6946575B2 (ja) | 2018-04-24 | 2021-10-06 | アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | 眼の状態の治療のためのピロカルピン塩酸塩の使用 |
| BR112021006618B1 (pt) | 2018-10-10 | 2022-09-27 | Presbyopia Therapies, Inc | Composições e métodos para o tratamento da presbiopia |
| US20210251970A1 (en) | 2018-10-10 | 2021-08-19 | Presbyopia Therapies Inc | Compositions and methods for storage stable ophthalmic drugs |
| DK3870170T3 (da) | 2018-10-26 | 2026-05-26 | Opus Genetics Inc | Behandling af presbyopi og mydriasis med fentolamin |
| WO2022104383A1 (en) * | 2020-11-13 | 2022-05-19 | Plex Pharmaceuticals, Inc. | Pharmacological agents for treating conditions of the eye |
| EP4419145A4 (de) * | 2021-10-19 | 2025-03-12 | VSY Biyoteknoloji Ve Ilac Sanayi Anonim Sirketi | Ophthalmische formulierungen zur behandlung von altersweitsichtigkeit, trockenem auge und computersichtsyndrom |
| WO2023091439A1 (en) | 2021-11-17 | 2023-05-25 | Lenz Therapeutics, Inc. | Aceclidine derivatives, compositions thereof and methods of use thereof |
| US11648247B1 (en) | 2021-12-16 | 2023-05-16 | Lenz Therapeutics, Inc. | Compositions and methods for the treatment of presbyopia |
| US12697253B2 (en) | 2022-12-09 | 2026-08-04 | ThruFocus Optics, LLC | Systems and methods for modulating laser treatment on the eye |
| US12414942B1 (en) | 2024-03-15 | 2025-09-16 | Lenz Therapeutics Operations, Inc. | Compositions, methods, and systems for treating presbyopia |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07508751A (ja) * | 1992-07-02 | 1995-09-28 | テラー・オフサルミック・ファーマシューティカルズ・インコーポレーテッド | 老視治療のための方法および生産品 |
| US5422116A (en) * | 1994-02-18 | 1995-06-06 | Ciba-Geigy Corporation | Liquid ophthalmic sustained release delivery system |
| US6291466B1 (en) * | 1998-07-30 | 2001-09-18 | Allergan Sales, Inc. | Cholinergic agents in the treatment of presbyopia |
| US6263879B1 (en) | 1998-11-10 | 2001-07-24 | J. T. Lin | Treatment of presbyopia and other eye disorders using a scanning laser system |
| US6258082B1 (en) | 1999-05-03 | 2001-07-10 | J. T. Lin | Refractive surgery and presbyopia correction using infrared and ultraviolet lasers |
| US6540990B2 (en) * | 2000-09-22 | 2003-04-01 | Gerard M. Nolan | Physiological method of improving vision |
| US6273092B1 (en) * | 2000-09-22 | 2001-08-14 | Gerard M. Nolan | Methods for treating various eye disorders |
| US20050205101A1 (en) * | 2002-10-17 | 2005-09-22 | Lin J T | Combined pharmocological and surgical method and system for the treatment of eye disorders |
| US20050119262A1 (en) * | 2003-08-21 | 2005-06-02 | Pharmacia Corporation | Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent |
-
2006
- 2006-12-18 AT AT06026169T patent/ATE439863T1/de active
- 2006-12-18 EP EP06026169A patent/EP1938839B1/de active Active
- 2006-12-18 ES ES06026169T patent/ES2329161T3/es active Active
- 2006-12-18 DK DK06026169T patent/DK1938839T3/da active
- 2006-12-18 DE DE602006008643T patent/DE602006008643D1/de active Active
- 2006-12-18 PT PT06026169T patent/PT1938839E/pt unknown
-
2007
- 2007-12-06 JP JP2009542246A patent/JP5769375B2/ja active Active
- 2007-12-06 MX MX2009006505A patent/MX2009006505A/es active IP Right Grant
- 2007-12-06 WO PCT/IB2007/003780 patent/WO2008075149A2/en not_active Ceased
- 2007-12-06 CA CA2672985A patent/CA2672985C/en active Active
- 2007-12-06 BR BRPI0720355A patent/BRPI0720355B8/pt active IP Right Grant
- 2007-12-06 US US12/519,910 patent/US8524758B2/en active Active
- 2007-12-06 AU AU2007335919A patent/AU2007335919B2/en active Active
-
2013
- 2013-03-14 US US13/827,183 patent/US20130197047A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP5769375B2 (ja) | 2015-08-26 |
| US20100016395A1 (en) | 2010-01-21 |
| US20130197047A1 (en) | 2013-08-01 |
| CA2672985A1 (en) | 2008-06-26 |
| EP1938839A1 (de) | 2008-07-02 |
| PT1938839E (pt) | 2009-09-30 |
| BRPI0720355B8 (pt) | 2023-01-24 |
| BRPI0720355B1 (pt) | 2019-02-05 |
| WO2008075149A2 (en) | 2008-06-26 |
| DK1938839T3 (da) | 2009-11-30 |
| MX2009006505A (es) | 2009-09-18 |
| CA2672985C (en) | 2013-06-11 |
| ES2329161T3 (es) | 2009-11-23 |
| EP1938839B1 (de) | 2009-08-19 |
| AU2007335919A1 (en) | 2008-06-26 |
| JP2010513454A (ja) | 2010-04-30 |
| WO2008075149A3 (en) | 2008-08-14 |
| BRPI0720355A2 (pt) | 2013-12-31 |
| AU2007335919B2 (en) | 2012-11-08 |
| US8524758B2 (en) | 2013-09-03 |
| DE602006008643D1 (de) | 2009-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602006008643D1 (de) | Ophthalmische Zusammensetzungen von parasympathischen Stimulantia und Entzündungshemmer zur Verwendung bei der Behandlung von Presbyopie | |
| DE602004017736D1 (de) | Verwendung von rapamycin und dessen derivaten zur behandlung von knochenverlust | |
| DE602006010401D1 (de) | Benzochinazolinderivate und ihre verwendung bei der behandlung von knochenerkrankungen | |
| ATE526991T1 (de) | Zusammensetzungen und ihre verwendungen für die gentherapeutische behandlung von knochenerkrankungen | |
| ATE554114T1 (de) | Copolymer mit zwitterionischen einheiten und anderen einheiten, das copolymer umfassende zusammensetzung und verwendung | |
| CY1111437T1 (el) | Τετραϋδροπυρρολοπυριμιδινοδιονες και η χρηση τους ως αναστολεων της ανθρωπινης ουδετεροφιλης ελαστασης | |
| ATE481984T1 (de) | Vakzine-peptid-kombinationen gegen katzenallergie | |
| EP1991055A4 (de) | Formulierungen, die ein nichtoxidatives biozid und eine quelle von aktivem halogen enthalten, und ihre verwendung bei der behandlung von wasser | |
| ATE474578T1 (de) | Verwendung von flibanserin bei der behandlung von prämenstruellen störungen | |
| EP1732484A4 (de) | Ophthalmisches implantat zur behandlung von glaukom | |
| DE60305200D1 (de) | Aminocyclohexylether-verbindungen und deren verwendung | |
| DE602006019468D1 (de) | Diarylharnstoffe zur behandlung von pulmonaler hypertonie | |
| DE602005019247D1 (de) | Verwendung von cyclodextrin zur behandlung und vorbeugung von entzündlichen bronchialerkrankungen | |
| ATE446753T1 (de) | Verwendung von substituierten 2-thio-3,5-dicyano- 4-phenyl-6-aminopyridinen bei der behandlung von übelkeit und erbrechen | |
| ATE472329T1 (de) | Verwendung der kombination von ciclesonid und antihistaminika zur behandlung von allergischer rhinitis | |
| ATE548035T1 (de) | Formulierungen zur behandlung von lipoprotein- anormalitäten mit einem statin- und einem methylnicotinamid-derivat | |
| DE602004022035D1 (de) | Verwendung von pthalide derivativen zur behandlung | |
| DE60206289D1 (de) | Verwendung von bibn4096 in kombination mit anderen migränemitteln zur behandlung von migräne | |
| EP1663283A4 (de) | Glutamin zur verwendung bei der behandlung von verletzungen | |
| ATE486878T1 (de) | Benzothienopyridine zur verwendung als inhibitoren von eg5-kinesin | |
| ATE504297T1 (de) | Visnadin zur behandlung von kopfhautjucken | |
| DE602006017367D1 (de) | Amino-oxo-indolyliden-verbindungen zur verwendung in der behandlung von juckender kopfhaut | |
| ATE397000T1 (de) | Tetrahydropyridothiophenen zur verwendung in der behandlung von krebs | |
| DE602006009786D1 (de) | Anwendung von molekülen und verfahren zur behandlung von mit mcp-1/ccr2 assoziierten krankheiten | |
| ATE410166T1 (de) | 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin- derivate zur behandlung von unfruchtbarkeit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1938839 Country of ref document: EP |